Study Finds Combination Therapy Produces Long-Term Mesothelioma Survival in Small Group of Patients, According to Surviving Mesothelioma

Share Article

New evidence suggests that a combination of chemotherapy and activation of a protein called CD40 may improve the survival odds for some patients with mesothelioma.

Long-Term Mesothelioma Survival with Combination Approach

Combination Therapy Produces Long-Term Mesothelioma Survival

Whilst objective response rates are similar to chemotherapy alone, three patients achieved long term survival.

Australian scientists say three mesothelioma patients lived more than twice as long as expected after treatment with a combination of chemotherapy and immune system manipulation. Surviving Mesothelioma has just posted an article on the new research. Click here to read it now.

In the study conducted at the University of Western Australia and Sir Charles Gairdner Hospital in Perth, 15 mesothelioma patients were given standard chemotherapy along with an antibody to activate a protein called CD40.

According to report author Dr. Anna K, Nowak, “Whilst objective response rates are similar to chemotherapy alone, three patients achieved long term survival.”

The study in the Annals of Oncology reports that three of the patients lived longer than 30 months after treatment. Life expectancy for most newly-diagnosed mesothelioma patients is about a year.

“Any time we hear a report about a treatment producing longer mesothelioma survival, we sit up and take notice,” says Alex Strauss, Managing Editor of Surviving Mesothelioma. “Not only does it mean that this particular treatment protocol may have merit, but it is a reminder that long term survival is possible.”

To read the details of this study, including the antibody used and the complications produced, see Long Term Mesothelioma Survival with Immune System Activation, now available on the Surviving Mesothelioma website.

Nowak, AK, et al, “A phase 1b clinical trial of the CD40 activating antibody CP-870,893 in combination with cisplatin and pemetrexed in malignant pleural mesothelioma”, September 18, 2015, Annals of Oncology, Epub ahead of print, http://annonc.oxfordjournals.org/content/early/2015/09/17/annonc.mdv387.abstract

For nearly ten years, Surviving Mesothelioma has brought readers the most important and ground-breaking news on the causes, diagnosis and treatment of mesothelioma. All Surviving Mesothelioma news is gathered and reported directly from the peer-reviewed medical literature. Written for patients and their loved ones, Surviving Mesothelioma news helps families make more informed decisions.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Michael Ellis
Cancer Monthy
+1 (919) 570-8595
Email >
Follow us on
Visit website